Wuhu Zhong Ren Pharmaceutical

Wuhu Zhongren Pharmaceutical is a specialized Chinese pharmaceutical company focused on the development and manufacturing of sustained-release drug delivery systems, particularly for oncology. The company is best known for its proprietary Fluorouracil Sustained-release Implants, which are used for local chemotherapy in various solid tumors to provide targeted, long-acting treatment while minimizing systemic toxicity. Founded in 2001 and headquartered in Wuhu, Anhui Province, the company operates as a key player in the interstitial chemotherapy market in China. Wuhu Zhongren was acquired by Grand Pharmaceutical Group, which has integrated the company's specialized implant technology into its broader innovative drug portfolio to enhance its oncology offerings.